Hope S. Rugo


Breast oncologist

About me

Dr. Hope Rugo is a hematologist-oncologist who specializes in breast cancer treatment. She joined the UCSF Carol Franc Buck Breast Care Center after a decade at UCSF Medical Center, where she worked in bone marrow transplantation for a variety of diseases, including breast cancer.

Rugo is co-director of UCSF's breast cancer clinical trials program. She is the principal investigator for several clinical trials of potential new therapies. She is also an investigator with the Bay Area's SPORE (Specialized Programs of Research Excellence) on breast cancer. The National Cancer Institute established SPORE to foster collaborative, interdisciplinary cancer research.

  • Education

    University of Pennsylvania School of Medicine, 1984

  • Residencies

    UCSF Medical Center, Internal Medicine, 1987

  • Fellowships

    UCSF Medical Center, Hematology, 1990

    UCSF Medical Center, Oncology, 1995

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title


  • Languages



Clinics I work with

Breast Care Center

Bakar Precision Cancer Medicine Building

1825 Fourth St., Third Floor
San Francisco, CA 94158

My reviews


Overall Experience
286 Reviews
I feel very lucky Dr. Rugo is my Oncologist. She is wise and compassionate I have total confidence in her.
Explained things in a way that was easy to understand
284 Reviews
Did the doctor pay attention to your concerns
281 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
274 Reviews
Knew the important information about your medical history
281 Reviews
The provider showed respect for what you had to say
284 Reviews
The provider spent enough time with me
285 Reviews
Decorative Caduceus

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo...

The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of se...


Decorative Caduceus

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positiv...


Decorative Caduceus

A Safety Study of SGN-LIV1A in Breast Cancer Patients

An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.


Decorative Caduceus

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small ...

Maximum Tolerated Dose (MTD) or recommended dose expansion (RDE) of DS-8201a (Part1) are based on the occurrence of DLTs.


Decorative Caduceus

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial C...

Number of Participants with DLTs and DLT-Equivalent Toxicities


Decorative Caduceus

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Che...

Complete response (CR), Partial Response (PR), and stable disease (SD)as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at 18 weeks of treatment in breast cancer patients with chest wall disease treated with ...


Decorative Caduceus

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer...

PFS is defined as the interval from the date of randomization to the earlier date of first documented radiographic progression or death due to any cause


Decorative Caduceus

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast...

Will create a comprehensive biorepository that includes blood, archival tissue, fresh tissue, and linked molecular and clinical data from patients with recurrent and/or metastatic breast cancer.


Decorative Caduceus

Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Neg...

Will be defined as the percentage of patients achieving complete response or partial response by RECIST version 1.1 and will be reported for each arm along with 95% two-sided confidence intervals.